Beta-elemene inhibits the growth of KDM6A-null bladder cancer cells by suppressing the epithelial-mesenchymal transition
Clinical Traditional Medicine and Pharmacology · 2024
DOI: 10.1016/j.ctmp.2024.200130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Traditional Medicine and Pharmacology, 2024. Verfasst von Ruonan Zhang und 6 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Bladder cancer is a highly prevalent and lethal malignant tumor characterized by frequent mutations/deletions of lysine-specific demethylase 6A (KDM6A), which is suggested to be a key event in cancer progression and metastasis. Beta-elemene has been shown to inhibit metastasis and growth of various tumors, but its effect on KDM6A-null bladder cancer cells remains unknown. This study aimed to investigate the potential and molecular mechanism of β-elemene in inhibiting the growth of KDM6A-null bladder cancer. This study examined the migration ability and viability of RT-4 (KDM6A wild-type) and KU19-19 (KDM6A-null) cell lines using wound healing assay and CCK-8, respectively. The inhibitory effect of β-elemene on KU19-19 cell migration was evaluated using transwell and immunofluorescence assays, and the expression of transfer-related proteins and genes was analyzed through western blot and qRT-PCR, respectively. Molecular docking was performed to predict the targeting of β-elemene, and the effects were confirmed in KDM6A-knockdown RT-4 cells. Finally, the therapeutic effect of β-elemene on bladder cancer was tested in animal models. The study observed that loss of KDM6A increased bladder cancer cell migration, with KU19-19 exhibiting significantly stronger migration than RT-4. Further investigation revealed that β-elemene effectively inhibited KU19-19 cell migration, likely through targeting EZH2 as determined by molecular docking. Overexpression of KDM6A inhibited KU19-19 metastasis, while knockdown of KDM6A in RT-4 cells enhanced cell migration, which was reversed by β-elemene treatment. Notably, in vivo testing revealed a significant suppression of KU19-19 cell growth with β-elemene administered at a dosage of 100 mg/kg. β-elemene has the potential to suppress the growth of KDM6A-null bladder cancer by inhibiting epithelial-mesenchymal transition (EMT), which could make it a promising therapeutic option for patients with KDM6A-null bladder cancer.
Zitieren
APA
Zhang, R., Feng, J., Zheng, Y., Zhu, Q., Xiang, B., Wu, Q., & Sui, X. (2024). Beta-elemene inhibits the growth of KDM6A-null bladder cancer cells by suppressing the epithelial-mesenchymal transition. Clinical Traditional Medicine and Pharmacology. https://doi.org/10.1016/j.ctmp.2024.200130
Vancouver
Zhang R, Feng J, Zheng Y, Zhu Q, Xiang B, Wu Q, et al. Beta-elemene inhibits the growth of KDM6A-null bladder cancer cells by suppressing the epithelial-mesenchymal transition. Clinical Traditional Medicine and Pharmacology. 2024. doi:10.1016/j.ctmp.2024.200130
BibTeX
@article{Zhang2024,
author = {Zhang, Ruonan and Feng, Jiao and Zheng, Yintao and Zhu, Qianru and Xiang, Bo and Wu, Qibiao and Sui, Xinbing},
title = {Beta-elemene inhibits the growth of KDM6A-null bladder cancer cells by suppressing the epithelial-mesenchymal transition},
journal = {Clinical Traditional Medicine and Pharmacology},
year = {2024},
doi = {10.1016/j.ctmp.2024.200130}
}
EUVIMED